Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer

  • End date
    May 1, 2023
  • participants needed
  • sponsor
    Medical College of Wisconsin
Updated on 4 October 2022


A Window of Opportunity Clinical Trial. This study design permits examination of effects of an oral agent on cancer patients during the "window" between diagnosis of their cancer and their definitive cancer surgery. Similar to a phase 0 study, the trial design permits examination of the biologic effects of an agent; in this study pharmacokinetic properties will be examined.


Study Intervention Description:

Study participants will take the natural botanical compound ATB during a short window (7 to 28 days). Participants will provide blood samples, and saliva samples during Anti-tumor B (ATB) administration and a portion of the initial tumor biopsy.

Condition Squamous Cell Carcinoma of the Oral Cavity
Treatment Antitumor B
Clinical Study IdentifierNCT03459729
SponsorMedical College of Wisconsin
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Clinical diagnosis of oral cavity squamous cell cancer
Patient can start study agent administration but histological confirmation of squamous cell cancer (SCC) of the oral cavity (or histologic variants of SCC) by the pathologist must happen within 7 days of registration in order to continue study agent administration
Clinical stage II-IVA (as defined by the American Joint Committee on Cancer, 8th Edition) and amenable to surgical resection
New diagnosis of oral SCC, new second primary, or recurrent oral SCC following a minimum remission of 6 months following previous definite surgery
History and physical examination by an otolaryngologist and medical oncologist within 14 calendar days of study registration
Study agent administration should start within 7 days of registration
Patient must receive administration of study agent for a minimum of 7 days
Zubrod Score/Eastern Cooperative Oncology Group (ECOG) Performance status < 2\
Age ≥ 18 years
Complete Blood Count (CBC)/differential obtained within 14 calendar days prior to registration, with adequate bone marrow function defined as follows
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3
Platelets ≥ 100,000 cells/mm^3
Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.)
Adequate renal and hepatic function within 14 calendar days prior to registration
defined as follows
Serum creatinine < 1.5 mg/dl or creatinine clearance (CCr) ≥ 50 ml/min within 14 calendar days prior to registration, determined by 24-hour collection or estimated by Cockcroft-Gault formula: CCr male = [(140 - age) x (wt in kg)] [(Serum Cr mg/dl) x (72)] CCr female = 0.85 x (CrCl male)
Total bilirubin < 2 x the institutional upper limit of normal (ULN) within 14 calendar
Magnesium, calcium, glucose, potassium, and sodium within 14 calendar days prior to registration, with the following required parameters
days prior to registration
Magnesium: > 0.9 mg/dl or < 3 mg/dl
aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 x the institutional ULN within 14 calendar days prior to registration
Calcium: > 7 mg/dl or < 12.5 mg/dl
Glucose: > 40 mg/dl or < 250 mg/dl
Potassium: > 3 mmol/L or < 6 mmol/L
Sodium: > 130 mmol/L or < 155 mmol/L
Female patients must meet one of the following
Postmenopausal for at least one year before the screening visit, or
Surgically sterile (e.g., undergone a hysterectomy or bilateral oophorectomy), or
If subject is of childbearing potential (defined as not satisfying either of the above two criteria), agree to practice two acceptable methods of contraception (combination methods requires use of two of the following: diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, hormonal contraceptive) from the time of signing of the informed consent form through 90 days after the last dose of study agent, AND
Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable contraception methods.)
Practice effective barrier contraception during the entire study period and through 60 calendar days after the last dose of study agent, OR
Must also adhere to the guidelines of any study-specific pregnancy prevention program, if applicable, OR
Male patients, even if surgically sterilized (e.g., status post vasectomy), must agree
Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post ovulation methods] and withdrawal are not acceptable methods of contraception.)
to one of the following
Patients must be deemed able to comply with the study plan
Gastric tube study agent administration is permissible
Patients must provide study-specific informed consent prior to study entry

Exclusion Criteria

History of active liver disease
Pregnant or lactating women are ineligible due to unforeseeable risks to embryo or fetus
Concurrent use of any medicinal botanical, natural, or other herbal compound/s that the study PI believes could potentially impact the results/objectives of this study
Planned subtotal or debulking surgery, as determined by enrolling physician determination, is not permissible
Prior systemic chemotherapy for oral SCC; note that prior chemotherapy for a different cancer is allowable
Prior radiotherapy for oral SCC is permissible if disease free for 1 year since prior oral cancer treatment and free of significant late radiation effects
Severe active comorbidity such as uncontrolled cardiac disease, infection, severe Chronic Obstructive Pulmonary Disease (COPD)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note